• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 16, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Mammography screening also confers benefits on participants with interval cancer

Bioengineer by Bioengineer
August 31, 2018
in Cancer
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Participants in the German mammography screening program (MSP) who have invasive breast cancer–including interval cancers–can on the whole undergo more sparing surgical treatment compared with non-participants. This is demonstrated by a study in the current issue of the Deutsches Ärzteblatt International (Dtsch Arztebl Int 2018; 115: 520-7). The tumor characteristics and prognostic markers of breast cancers detected in MSP participants at screening, in the interval following negative screening, as well as in non-participants were compared.

Data on 1531 newly diagnosed cases of invasive and in situ breast cancer (DCIS, ductal carcinoma in situ) were evaluated in two certified breast care centers in Münster, Germany. Comprehensive information on tumor characteristics, tumor biology, and primary surgical treatment was available for all cases. In their retrospective observational study, Bettina Braun and co-authors conclude that breast cancer was still at an early stage (DCIS) more frequently in screening participants compared with non-participants (23% versus 31%). Invasive cancers were smaller in participants (74% versus 55% in the T1 stage), could be operated on more frequently in a breast-conserving manner (75% versus 62%), and a guideline-based indication for adjuvant chemotherapy was less common in these patients (46% versus 52%). The authors emphasize that one can assume comparable figures in other screening regions.

###

https://www.aerzteblatt.de/pdf.asp?id=199287

Media Contact

Dr. Hans-Werner Hense
[email protected]

http://www.aerzteblatt-international.de/int/

http://dx.doi.org/10.3238/arztebl.2018.0520

Share14Tweet8Share2ShareShareShare2

Related Posts

blank

Exploring the Gut-Heart Link: How Microbiota Influence Heart Failure

August 16, 2025
blank

ADAMTS2: Unlocking the Therapeutic Potential of a Multifunctional Protein

August 16, 2025

Exploring the Impact of Fucosylation in Digestive Diseases and Cancer

August 16, 2025

Groundbreaking Discoveries in Tumor Angiogenesis and the Origins of Endothelial Cells

August 15, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    140 shares
    Share 56 Tweet 35
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    79 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    59 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    47 shares
    Share 19 Tweet 12

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Leveraging Virtual Reality to Combat Substance Use Relapse

Exploring the Gut-Heart Link: How Microbiota Influence Heart Failure

ADAMTS2: Unlocking the Therapeutic Potential of a Multifunctional Protein

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.